Filing Flows › Tarsus Pharmaceuticals (TARS) › R&D spending
Tarsus Pharmaceuticals (TARS) R&D spending by quarter
Tarsus Pharmaceuticals' R&D spending was $44.2M in Q3 2026 (third quarter 2026), +43% from Q2 2026. Over the last 7 quarters it ranged from $14.4M (Q1 2025) to $44.2M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $44.2M | +43% | +171% |
| Q2 2026 | $31.0M | +39% | +99% |
| Q1 2026 | $22.4M | +24% | +55% |
| Q4 2025 | $18.0M | +11% | — |
| Q3 2025 | $16.3M | +4% | — |
| Q2 2025 | $15.6M | +8% | — |
| Q1 2025 | $14.4M | — | — |
Q3 2026 at a glance
Tarsus Pharmaceuticals, Q3 2026: revenue $195M (+64% year over year), operating margin -340.3%, net loss $668M, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Tarsus Pharmaceuticals' R&D spending?
Tarsus Pharmaceuticals' R&D spending was $44.2M in Q3 2026 (third quarter 2026), +43% from Q2 2026.
How has Tarsus Pharmaceuticals' R&D spending changed?
Over the last 7 quarters it ranged from $14.4M (Q1 2025) to $44.2M (Q3 2026).
Q3 2026 results → · How Tarsus Pharmaceuticals makes money →